Danielle Colato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danielle Colato has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Malaspina
Department of Neuromuscular Diseases, UCL Queen Square Motor Neuron Disease Center, UCL Queen Square Institute of Neurology, University College London, London, UK
1 shared publication Anne-Laure Grignon
Department of Neurology and ALS Center, University of Miami Miller School of Medicine, Miami, USA
1 shared publication- Christina M. Lill
Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany
1 shared publication - Elizabeth Lin
Department of Neuromuscular Diseases, UCL Queen Square Motor Neuron Disease Center, UCL Queen Square Institute of Neurology, University College London, London, UK
1 shared publication - Joanne Wuu
Department of Neurology and the ALS Center, Miller School of Medicine, University of Miami , Miami, FL 33129
1 shared publication - Johnathan Cooper-Knock
University of Sheffield
1 shared publication
Latest Publications
- Open Access
- 27 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3417-3429
Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS
The study of pre-symptomatic amyotrophic lateral sclerosis (ALS) and the design of disease prevention trials are greatly hampered by our inability to predict which unaffected carriers of ALS-associated pathogenic variants will phenoconvert to clinically manifest disease and when. In this longitudinal Olink Explore, high-throughput, proteomic study, 516 serially collected plasma samples from 33 phenoconverters, 35 patients with ALS, 10 pre-symptomatic pathogenic variant carriers and 59 controls were included. Here we identified 92 proteins with concentrations that changed before phenoconversion; characterized the longitudinal trajectory of these proteins and identified a core panel of 19 proteins which, collectively, predicted phenoconversion over the 0.5-year to 5-year time horizons (crossvalidated areas under the curve 0.80–0.89) and yielded estimates of time to phenoconversion with a mean absolute error of 1.6 years. These findings were partially replicated in UK Biobank data, confirming pre-symptomatic increases in several proteins (for example, NEFL, EDA2R and CA3) and that a multi-protein panel outperformed NEFL alone in estimating time to phenoconversion. This work sheds light on the biology of pre-symptomatic ALS. Moreover, our identification of a panel of new susceptibility/risk biomarkers based on empirical longitudinal data furthers the ultimate goal of ALS prevention.
- 27 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3417-3429
Open AccessLongitudinal plasma proteomics predict phenoconversion to clinically manifest ALS
The study of pre-symptomatic amyotrophic lateral sclerosis (ALS) and the design of disease prevention trials are greatly hampered by our inability to predict which unaffected carriers of ALS-associated pathogenic variants will phenoconvert to clinically manifest disease and when. In this longitudinal Olink Explore, high-throughput, proteomic study, 516 serially collected plasma samples from 33 phenoconverters, 35 patients with ALS, 10 pre-symptomatic pathogenic variant carriers and 59 controls were included. Here we identified 92 proteins with concentrations that changed before phenoconversion; characterized the longitudinal trajectory of these proteins and identified a core panel of 19 proteins which, collectively, predicted phenoconversion over the 0.5-year to 5-year time horizons (crossvalidated areas under the curve 0.80–0.89) and yielded estimates of time to phenoconversion with a mean absolute error of 1.6 years. These findings were partially replicated in UK Biobank data, confirming pre-symptomatic increases in several proteins (for example, NEFL, EDA2R and CA3) and that a multi-protein panel outperformed NEFL alone in estimating time to phenoconversion. This work sheds light on the biology of pre-symptomatic ALS. Moreover, our identification of a panel of new susceptibility/risk biomarkers based on empirical longitudinal data furthers the ultimate goal of ALS prevention.